Alto Neuroscience (NYSE:ANRO) COO Jr. Michael Conick Hanley Sells 2,104 Shares of Stock

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) COO Michael Hanley sold 2,104 shares of Alto Neuroscience stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $26.82, for a total transaction of $56,429.28. Following the completion of the sale, the chief operating officer directly owned 17,729 shares in the company, valued at $475,491.78. This trade represents a 10.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jr. Michael Conick Hanley also recently made the following trade(s):

  • On Wednesday, November 18th, Michael Hanley sold 2,896 shares of Alto Neuroscience stock. The shares were sold at an average price of $26.48, for a total value of $76,686.08.
  • On Monday, November 16th, Michael Hanley sold 70,000 shares of Alto Neuroscience stock. The shares were sold at an average price of $27.68, for a total value of $1,937,600.00.

Alto Neuroscience Stock Up 3.4%

NYSE:ANRO opened at $25.77 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.12 and a quick ratio of 18.12. The business has a fifty day simple moving average of $25.83 and a two-hundred day simple moving average of $24.79. Alto Neuroscience, Inc. has a 1 year low of $12.51 and a 1 year high of $37.48.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.13. On average, analysts anticipate that Alto Neuroscience, Inc. will post -2.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ANRO. Wedbush lifted their price objective on Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. BTIG Research reaffirmed a “buy” rating and set a $37.00 price objective on shares of Alto Neuroscience in a report on Wednesday, November 11th. Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Finally, Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.88.

Get Our Latest Stock Analysis on Alto Neuroscience

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its position in shares of Alto Neuroscience by 70.9% during the third quarter. Goldman Sachs Group Inc. now owns 404,674 shares of the company’s stock worth $10,331,000 after acquiring an additional 167,844 shares in the last quarter. Bellevue Group AG bought a new position in shares of Alto Neuroscience in the third quarter worth $29,706,000. Marshall Wace LLP boosted its holdings in shares of Alto Neuroscience by 281.1% in the third quarter. Marshall Wace LLP now owns 859,309 shares of the company’s stock worth $21,938,000 after acquiring an additional 633,806 shares during the period. Empowered Funds LLC bought a new position in shares of Alto Neuroscience in the third quarter worth $299,000. Finally, HighVista Strategies LLC purchased a new position in shares of Alto Neuroscience in the third quarter valued at $922,000.

Top Alto Neuroscience Stories

These are some of the ANRO stories that stood out recently:

  • Positive Sentiment: Alto reported a quarterly loss of $0.54 per share, narrower than the $0.67 loss analysts expected. That earnings beat may offer some support, though the company’s loss widened compared with the prior-year period. Alto Neuroscience reports wider quarterly loss and valuation analysis
  • Neutral Sentiment: A recent analysis questioned whether ANRO’s premium valuation is justified. This highlights valuation risk but does not provide a new company-specific catalyst. Alto Neuroscience valuation analysis
  • Negative Sentiment: COO Jr. Michael Conick Hanley disclosed selling shares, including a 70,000-share transaction and smaller sales. The reported reduction in his holdings could concern investors, although insider sales alone do not establish the company’s outlook. SEC Form 4 filing

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.

Further Reading

Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.